Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …

Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …

Background Lung adenocarcinomas from patients who respond to the tyrosine kinase
inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function …

Introduction: The epidermal growth factor receptor (EGFR) and its family members are
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …

Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …

Patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer
derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors …

Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …

Background Somatic mutations in the epidermal growth factor receptor (EGFR) gene are a
predictor of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with …

EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current …